NasdaqGM:OBLN

Stock Analysis Report

Executive Summary

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight.

Snowflake

Fundamentals

Imperfect balance sheet with limited growth.


Similar Companies

Share Price & News

How has Obalon Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.1%

OBLN

1.9%

US Medical Equipment

0.4%

US Market


1 Year Return

-90.9%

OBLN

15.6%

US Medical Equipment

6.9%

US Market

Return vs Industry: OBLN underperformed the US Medical Equipment industry which returned 15.6% over the past year.

Return vs Market: OBLN underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

OBLNIndustryMarket
7 Day7.1%1.9%0.4%
30 Day-16.7%-1.7%-1.1%
90 Day-75.3%-0.03%-0.5%
1 Year-90.9%-90.9%16.5%15.6%9.3%6.9%
3 Year-98.7%-98.7%72.1%66.9%45.8%36.4%
5 Yearn/a125.8%100.8%62.9%45.1%

Price Volatility Vs. Market

How volatile is Obalon Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Obalon Therapeutics undervalued compared to its fair value and its price relative to the market?

0.76x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OBLN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OBLN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OBLN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: OBLN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OBLN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OBLN is good value based on its PB Ratio (0.8x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Obalon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

21.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OBLN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OBLN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OBLN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OBLN's revenue (66.6% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: OBLN's revenue (66.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OBLN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Obalon Therapeutics performed over the past 5 years?

-25.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: OBLN is unprofitable, and losses have increased over the past 5 years at a rate of -25.8% per year.

Accelerating Growth: Unable to compare OBLN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OBLN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: OBLN has a negative Return on Equity (-364.35%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: OBLN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: OBLN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Obalon Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: OBLN's short term assets ($17.0M) exceeds its short term liabilities ($10.1M)

Long Term Liabilities: OBLN's short term assets (17.0M) exceeds its long term liabilities (722.0K)


Debt to Equity History and Analysis

Debt Level: OBLN's debt to equity ratio (59.6%) is considered high

Reducing Debt: Insufficient data to determine if OBLN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: OBLN has a high level of physical assets or inventory.

Debt Coverage by Assets: OBLN's debt is covered by short term assets (assets are 3.404200x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OBLN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OBLN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -17% each year


Next Steps

Dividend

What is Obalon Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate OBLN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OBLN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if OBLN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OBLN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OBLN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Obalon Therapeutics's salary, the management and board of directors tenure and is there insider trading?

0.4yrs

Average management tenure


CEO

Obalon Therapeutics has no CEO, or we have no data on them.


Management Age and Tenure

0.4yrs

Average Tenure

53.5yo

Average Age

Experienced Management: OBLN's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.


Board Age and Tenure

3.7yrs

Average Tenure

56.5yo

Average Age

Experienced Board: OBLN's board of directors are considered experienced (3.7 years average tenure).


Insider Trading

Insider Buying: OBLN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$50,00008 Aug 19
Kim Kamdar
EntityIndividual
Role
Member of the Board of Directors
Director
Shares12,500
Max PriceUS$4.00
BuyUS$1,000,00008 Aug 19
Domain Associates, L.L.C.
EntityCompany
Shares250,000
Max PriceUS$4.00
BuyUS$20,00008 Aug 19
Nooshin Hussainy
EntityIndividual
Shares5,000
Max PriceUS$4.00
BuyUS$20,00008 Aug 19
Mark Brister
EntityIndividual
Role
Chief Technology Officer
Chief Technology Officer
Shares5,000
Max PriceUS$4.00
BuyUS$20,00008 Aug 19
Robert Macdonald
EntityIndividual
Role
Senior Key Executive
Chief Retail Officer
Shares5,000
Max PriceUS$4.00
BuyUS$10,00008 Aug 19
Amy VandenBerg
EntityIndividual
Role
Senior Key Executive
Chief Quality Assurance
Shares2,500
Max PriceUS$4.00
BuyUS$50,00008 Aug 19
William Plovanic
EntityIndividual
Role
Member of the Board of Directors
President
Shares12,500
Max PriceUS$4.00
BuyUS$50,00008 Aug 19
Andrew Rasdal
EntityIndividual
Role
Chairman of the Board
Executive Chairman of the Board
Shares12,500
Max PriceUS$4.00
BuyUS$30,00008 Aug 19
Sharon Stevenson
EntityIndividual
Role
Member of the Board of Directors
Director
Shares7,500
Max PriceUS$4.00
BuyUS$25,00008 Aug 19
Lesley Howe
EntityIndividual
Role
Member of the Board of Directors
Director
Shares6,250
Max PriceUS$4.00
BuyUS$100,00008 Aug 19
InterWest Partners LLC
EntityCompany
Shares25,000
Max PriceUS$4.00

Ownership Breakdown


Management Team

  • Andy Rasdal (61yo)

    Executive Chairman of the Board

    • Tenure: 0.8yrs
    • Compensation: US$2.32m
  • Mark Brister (57yo)

    Chief Technology Officer

    • Tenure: 2.9yrs
    • Compensation: US$486.81k
  • William Plovanic (50yo)

    President

    • Tenure: 0.4yrs
    • Compensation: US$1.07m
  • Kelly Huang (50yo)

    Consultant

    • Tenure: 0.4yrs
    • Compensation: US$1.13m
  • Amy VandenBerg (44yo)

    Chief Quality Assurance

    • Tenure: 0.8yrs
    • Compensation: US$347.89k
  • Bob Macdonald (59yo)

    Chief Retail Officer

    • Tenure: 0.4yrs

Board Members

  • Andy Rasdal (61yo)

    Executive Chairman of the Board

    • Tenure: 0.8yrs
    • Compensation: US$2.32m
  • Sharon Stevenson (70yo)

    Director

    • Tenure: 11.8yrs
    • Compensation: US$142.44k
  • Ray Dittamore (76yo)

    Director

    • Tenure: 3.6yrs
    • Compensation: US$154.94k
  • Les Howe (74yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$157.44k
  • Kim Kamdar (52yo)

    Director

    • Tenure: 11.8yrs
    • Compensation: US$169.94k
  • Doug Fisher (43yo)

    Director

    • Tenure: 7.4yrs
    • Compensation: US$139.94k
  • William Plovanic (50yo)

    President

    • Tenure: 0.4yrs
    • Compensation: US$1.07m
  • David Moatazedi (41yo)

    Director

    • Tenure: 2.6yrs
    • Compensation: US$147.44k

Company Information

Obalon Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Obalon Therapeutics, Inc.
  • Ticker: OBLN
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$9.979m
  • Shares outstanding: 5.54m
  • Website: https://www.obalon.com

Number of Employees


Location

  • Obalon Therapeutics, Inc.
  • 5421 Avenida Encinas
  • Suite F
  • Carlsbad
  • California
  • 92008
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OBLNNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDOct 2016
24OADB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2016

Biography

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Oba ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 00:27
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.